Sigma Investment Counselors Inc. Makes New Investment in Enlivex Therapeutics Ltd. (NASDAQ:ENLV)

Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,000 shares of the company’s stock, valued at approximately $50,000.

Separately, XTX Topco Ltd purchased a new position in shares of Enlivex Therapeutics during the 2nd quarter worth $35,000. 1.02% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. EF Hutton Acquisition Co. I raised Enlivex Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 27th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Enlivex Therapeutics in a report on Friday, September 27th.

Enlivex Therapeutics Stock Down 3.3 %

ENLV stock opened at $1.47 on Friday. The company has a market cap of $30.68 million, a price-to-earnings ratio of -1.06 and a beta of 1.04. The business has a fifty day simple moving average of $1.44 and a 200-day simple moving average of $1.45. Enlivex Therapeutics Ltd. has a 52 week low of $1.15 and a 52 week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings data on Friday, August 30th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. As a group, analysts expect that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.